These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1018 related articles for article (PubMed ID: 28556970)
1. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8 Yin W; Song Y; Liu Q; Wu Y; He R Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970 [TBL] [Abstract][Full Text] [Related]
2. Chemerin partly mediates tumor-inhibitory effect of all-trans retinoic acid via CMKLR1-dependent natural killer cell recruitment. Song Y; Yin W; Dan Y; Sheng J; Zeng Y; He R Immunology; 2019 Jul; 157(3):248-256. PubMed ID: 31063220 [TBL] [Abstract][Full Text] [Related]
3. STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity. Rossi M; Carboni S; Di Berardino-Besson W; Riva E; Santiago-Raber ML; Belnoue E; Derouazi M Front Immunol; 2021; 12():695056. PubMed ID: 34276686 [TBL] [Abstract][Full Text] [Related]
4. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach. Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608 [TBL] [Abstract][Full Text] [Related]
5. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609 [TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells. Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites. Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543 [TBL] [Abstract][Full Text] [Related]
8. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner. Yu R; Jin L; Li F; Fujimoto M; Wei Q; Lin Z; Ren X; Jin Q; Li H; Meng F; Jin G J Dermatol Sci; 2020 Sep; 99(3):193-202. PubMed ID: 32859456 [TBL] [Abstract][Full Text] [Related]
10. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3. Tang Q; Jiang J; Liu J Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948 [TBL] [Abstract][Full Text] [Related]
11. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. Riquelme E; Carreño LJ; González PA; Kalergis AM Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198 [TBL] [Abstract][Full Text] [Related]
12. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060 [TBL] [Abstract][Full Text] [Related]
13. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536 [TBL] [Abstract][Full Text] [Related]
14. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930 [TBL] [Abstract][Full Text] [Related]